Stay updated on Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page footer now shows Revision: v3.3.3, and the HHS Vulnerability Disclosure link along with the Revision: v3.3.2 note were removed. These are minor maintenance updates that do not affect core study content or functionality; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedAdded a PubMed publications note indicating automatic population of publications and updated the revision tag to v3.3.2.SummaryDifference0.1%

- Check46 days agoChange DetectedRemoved the banner about a lapse in government funding; no other study-related content appears to have changed.SummaryDifference0.3%

- Check60 days agoChange DetectedNo additions or deletions were detected on the page; the study details appear unchanged.SummaryDifference0.4%

- Check89 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%

- Check96 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new software release.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.